Findings Presented at the ASCO-SITC 2020 Clinical Immuno-Oncology Symposium Orlando, FL and Culver City, CA – February 19, 2020 –...
NantHealth Presented These Findings at the ASCO 2020 Gastrointestinal Cancers Symposium SAN FRANCISCO–(BUSINESS WIRE)–Jan. 25, 2020– NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based,...
NantHealth’s Liquid GPS™ technology shows promise in the monitoring of key biomarkers in metastatic colorectal cancer MUNICH and CULVER CITY,...
Platinum sponsor NantHealth will showcase GPS Cancer® and precision medicine solutions for oncology at booth #314 Culver City, California and...
Partnership enables oncologists in Singapore, Malaysia, Thailand, Vietnam and The Philippines to offer patients a new standard of care through GPS Cancer NantHealth expands global GPS Cancer launch...
Sistemas Medicos Nacionales becomes first international payer to cover GPS CancerTM for patients, bringing a new standard of cancer care...
CULVER CITY, Calif.--Mar. 10, 2017-- NantHealth, Inc. (NASDAQ-GS: NH),
Led by the Division of Neurosurgery and Center for Data Driven Discovery at the Children's Hospital of Philadelphia, the Philadelphia...
Florida-based community oncologists leverage advanced molecular profile for decision support Doctors report that patients find hope in additional care options...
Patients and physicians can now access active clinical trials for various cancer types including lung, breast, leukemia and more through...
Randomized (TASTE) Trial In Early Stage Non-Small Cell Lung Cancer Trial, Demonstrates That GPS Proteomics Analysis Could Predict Tumor Response...
Company continues strong momentum for its comprehensive molecular test for cancer care and driving the era of clinical proteomics by...